Need for mechanical ventilation · patients with the management of transient tachypnea of the newborn
It is very uncertain whether inhaled corticosteroids changes need for mechanical ventilation compared with no treatment or placebo (very low certainty).
1 finding from 1 review
Length of hospital stay · patients with the management of transient tachypnea of the newborn
1 finding from 1 review
Duration of tachypnoea · patients with the management of transient tachypnea of the newborn
1 finding from 1 review
Persistent pulmonary hypertension · patients with the management of transient tachypnea of the newborn
1 finding from 1 review
Hyperglycaemia · patients with the management of transient tachypnea of the newborn
1 finding from 1 review
Gastrointestinal bleed · patients with the management of transient tachypnea of the newborn
1 finding from 1 review
Lung function: FEV1 mL (change from baseline) · people with bronchiectasis
1 finding from 1 review
Number of participants improved · people with bronchiectasis
Inhaled corticosteroids showed no clear difference in number of participants improved compared with placebo (low certainty).
1 finding from 1 review
Lung function (spirometry indices) ‐ FVC (in L, end study minus baseline values) · people with bronchiectasis
1 finding from 1 review
Lung function (other indices) ‐ diffusion capacity % predicted (end of study) · people with bronchiectasis
1 finding from 1 review
Lung function (other indices) ‐ RV % predicted (end of study values) · people with bronchiectasis
1 finding from 1 review
Lung function (other indices) ‐ TLC % predicted (end of study values) · people with bronchiectasis
1 finding from 1 review
Exacerbations · people with bronchiectasis
1 finding from 1 review
Pseudomonas aeruginosa (P aeruginosa) colonisation · people with bronchiectasis
Inhaled corticosteroids showed no clear difference in pseudomonas aeruginosa (P aeruginosa) colonisation compared with placebo (low certainty).
1 finding from 1 review
FEV1 % predicted: absolute change from baseline · people with bronchiectasis
1 finding from 1 review
FVC (% predicted) Change from baseline · people with bronchiectasis
1 finding from 1 review
Worse or unimproved within 5 weeks from randomisation · multiple sclerosis patients with acute exacerbations
Corticosteroids or ACTH probably leads to lower worse or unimproved within 5 weeks from randomisation compared with placebo (moderate certainty).
1 finding from 1 review
Mean disability (EDSS) score—at 1 week after randomisation · multiple sclerosis patients with acute exacerbations
Corticosteroids or ACTH showed no clear difference in mean disability (EDSS) score—at 1 week after randomisation compared with placebo (moderate certainty).
1 finding from 1 review
Participants with new exacerbations during · multiple sclerosis patients with acute exacerbations
It is very uncertain whether corticosteroids or ACTH changes participants with new exacerbations during compared with placebo (very low certainty).
1 finding from 1 review
Complete remission · minimal change disease in adults with nephrotic syndrome
Mycophenolate sodium + oral steroids showed no clear difference in complete remission Time frame: 4 weeks compared with oral steroids alone (moderate certainty).
2 findings from 1 review